Collegium Pharmaceutical Stock News

Needham analyst Serge Belanger maintained a Buy rating on KalVista Pharmaceuticals (KALV) today and set a price target of $28.00. The company's shares

Needham analyst Serge Belanger maintained a Buy rating on KalVista Pharmaceuticals ( KALV – Research Report ) today and set a price target of $28.00 . The company’s shares closed last Wednesday at

Collegium Pharmaceutical Inc (NASDAQ:COLL) – Equities research analysts at G.Research cut their FY2023 earnings per share estimates for Collegium Pharmaceutical in a report released on Monday, April

Collegium Pharmaceutical Inc (NASDAQ:COLL) – Equities research analysts at G.Research lowered their FY2020 earnings per share estimates for Collegium Pharmaceutical in a report released on Monday, A

Axovant Sciences (NASDAQ:AXON) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strengt

In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Teva Pharmaceutical Industries (TEVA), with a price target of

In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Teva Pharmaceutical Industries ( TEVA – Research Report ), with a price target of $8.00 . The company’s sh

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bioxcel Therapeutics (BTAI), Madrigal Pharmaceuticals

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bioxcel Therapeutics

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Entasis Therapeutics Holdings (ETTX) today and set a price target of $5.00. The company's

Needham analyst Serge Belanger maintained a Buy rating on Collegium Pharmaceutical (COLL) today and set a price target of $38.00. The company's shares

AQR Capital Management LLC bought a new stake in shares of Collegium Pharmaceutical Inc (NASDAQ:COLL) during the fourth quarter, according to the company in its most recent 13F filing with the Securit

Zacks Investment Research downgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a buy rating to a hold rating in a research note issued to investors on Wednesday, Zacks.com reports. Accordi

In a report released yesterday, Tim Lugo from William Blair maintained a Buy rating on Albireo Pharma (ALBO). The company's shares closed last Thursday at

In a report released yesterday, Tim Lugo from William Blair maintained a Buy rating on Albireo Pharma (ALBO – Research